These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14998865)

  • 1. Coronary ischemia related to alemtuzumab therapy.
    Basquiera AL; Berretta AR; García JJ; Palazzo ED
    Ann Oncol; 2004 Mar; 15(3):539-40. PubMed ID: 14998865
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
    Goodman M
    J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab for treatment of lymphoproliferative disorders.
    Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
    Anoop P; Wotherspoon A; Matutes E
    Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
    [No Abstract]   [Full Text] [Related]  

  • 6. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
    Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
    Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campath-1H for chronic lymphocytic leukemia.
    Rai KR
    Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
    Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
    Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
    [No Abstract]   [Full Text] [Related]  

  • 9. Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.
    Ammatuna E; Sarlo C; Ottaviani L; Quaresima M; Buccisano F; Campagna S; Del Principe MI; De Angelis G; Anemona L; Gumenyuk S; Amadori S; Venditti A
    Leuk Lymphoma; 2009 May; 50(5):857-8. PubMed ID: 19330655
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
    Osterborg A; Mellstedt H; Keating M
    Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.
    Kunz JS; Bannerji R
    Leuk Lymphoma; 2005 Apr; 46(4):635-7. PubMed ID: 16019499
    [No Abstract]   [Full Text] [Related]  

  • 13. A fatal case of alemtuzumab-associated interstitial pneumonitis.
    Creelan B; Ferber A
    Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics].
    Doubek M; Jungová A; Brejcha M; Panovská A; Brychtová Y; Pospísil Z; Mayer J;
    Vnitr Lek; 2009 Jun; 55(6):549-54. PubMed ID: 19662885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
    Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
    Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
    Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
    Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
    Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
    [No Abstract]   [Full Text] [Related]  

  • 18. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
    Smolej L
    Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576
    [No Abstract]   [Full Text] [Related]  

  • 19. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.